Hunan Hansen Pharmaceutical Co Ltd (002412) - Net Assets
Based on the latest financial reports, Hunan Hansen Pharmaceutical Co Ltd (002412) has net assets worth CN¥2.42 Billion CNY (≈ $354.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.73 Billion ≈ $399.99 Million USD) and total liabilities (CN¥310.49 Million ≈ $45.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hunan Hansen Pharmaceutical Co Ltd (002412) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.42 Billion |
| % of Total Assets | 88.64% |
| Annual Growth Rate | 20.65% |
| 5-Year Change | 36.65% |
| 10-Year Change | 89.19% |
| Growth Volatility | 87.7 |
Hunan Hansen Pharmaceutical Co Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Hunan Hansen Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hunan Hansen Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual net assets of Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2025. For live valuation and market cap data, see how much is Hunan Hansen Pharmaceutical Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.38 Billion ≈ $348.40 Million |
+8.06% |
| 2024-12-31 | CN¥2.20 Billion ≈ $322.42 Million |
+12.24% |
| 2023-12-31 | CN¥1.96 Billion ≈ $287.25 Million |
+3.64% |
| 2022-12-31 | CN¥1.89 Billion ≈ $277.17 Million |
+8.71% |
| 2021-12-31 | CN¥1.74 Billion ≈ $254.95 Million |
+9.25% |
| 2020-12-31 | CN¥1.59 Billion ≈ $233.36 Million |
+4.23% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.88 Million |
+12.22% |
| 2018-12-31 | CN¥1.36 Billion ≈ $199.50 Million |
+11.82% |
| 2017-12-31 | CN¥1.22 Billion ≈ $178.41 Million |
-3.12% |
| 2016-12-31 | CN¥1.26 Billion ≈ $184.16 Million |
+0.40% |
| 2015-12-31 | CN¥1.25 Billion ≈ $183.42 Million |
+8.70% |
| 2014-12-31 | CN¥1.15 Billion ≈ $168.75 Million |
+4.11% |
| 2013-12-31 | CN¥1.11 Billion ≈ $162.08 Million |
+14.77% |
| 2012-12-31 | CN¥965.11 Million ≈ $141.23 Million |
+9.22% |
| 2011-12-31 | CN¥883.65 Million ≈ $129.31 Million |
-1.69% |
| 2010-12-31 | CN¥898.82 Million ≈ $131.53 Million |
+400.71% |
| 2009-12-31 | CN¥179.51 Million ≈ $26.27 Million |
+37.81% |
| 2008-12-31 | CN¥130.26 Million ≈ $19.06 Million |
+48.42% |
| 2007-12-31 | CN¥87.77 Million ≈ $12.84 Million |
+30.46% |
| 2006-12-31 | CN¥67.28 Million ≈ $9.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Hansen Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3754.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.43 Billion | 60.09% |
| Other Components | CN¥950.14 Million | 39.91% |
| Total Equity | CN¥2.38 Billion | 100.00% |
Hunan Hansen Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Hansen Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LB Foster Company
NASDAQ:FSTR
|
$436.75 Million |
|
Issta Lines Ltd
TA:ISTA
|
$436.86 Million |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
$436.90 Million |
|
Savita Oil Technologies Limited
NSE:SOTL
|
$437.01 Million |
|
Evolus Inc
NASDAQ:EOLS
|
$436.62 Million |
|
Aeluma, Inc
NASDAQ:ALMU
|
$436.61 Million |
|
Hangzhou Zhongya Machinery Co Ltd
SHE:300512
|
$436.56 Million |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
$436.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Hansen Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,203,382,060 to 2,380,923,605, a change of 177,541,545 (8.1%).
- Net income of 198,120,449 contributed positively to equity growth.
- Dividend payments of 1,725,347 reduced retained earnings.
- Other comprehensive income decreased equity by 222,876,857.
- Other factors increased equity by 204,023,300.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥198.12 Million | +8.32% |
| Dividends Paid | CN¥1.73 Million | -0.07% |
| Other Comprehensive Income | CN¥-222.88 Million | -9.36% |
| Other Changes | CN¥204.02 Million | +8.57% |
| Total Change | CN¥- | 8.06% |
Book Value vs Market Value Analysis
This analysis compares Hunan Hansen Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 43.13x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.14 | CN¥5.93 | x |
| 2007-12-31 | CN¥0.24 | CN¥5.93 | x |
| 2008-12-31 | CN¥0.35 | CN¥5.93 | x |
| 2009-12-31 | CN¥0.48 | CN¥5.93 | x |
| 2010-12-31 | CN¥2.00 | CN¥5.93 | x |
| 2011-12-31 | CN¥1.77 | CN¥5.93 | x |
| 2012-12-31 | CN¥1.92 | CN¥5.93 | x |
| 2013-12-31 | CN¥2.14 | CN¥5.93 | x |
| 2014-12-31 | CN¥2.23 | CN¥5.93 | x |
| 2015-12-31 | CN¥2.42 | CN¥5.93 | x |
| 2016-12-31 | CN¥2.50 | CN¥5.93 | x |
| 2017-12-31 | CN¥2.42 | CN¥5.93 | x |
| 2018-12-31 | CN¥2.71 | CN¥5.93 | x |
| 2019-12-31 | CN¥3.04 | CN¥5.93 | x |
| 2020-12-31 | CN¥3.17 | CN¥5.93 | x |
| 2021-12-31 | CN¥3.46 | CN¥5.93 | x |
| 2022-12-31 | CN¥3.76 | CN¥5.93 | x |
| 2023-12-31 | CN¥3.90 | CN¥5.93 | x |
| 2024-12-31 | CN¥4.38 | CN¥5.93 | x |
| 2025-12-31 | CN¥4.73 | CN¥5.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Hansen Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.07%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.13x
- Recent ROE (8.32%) is below the historical average (13.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 21.39% | 8.87% | 0.60x | 4.03x | CN¥5.99 Million |
| 2007 | 43.15% | 22.69% | 0.96x | 1.99x | CN¥29.10 Million |
| 2008 | 32.62% | 18.03% | 1.10x | 1.65x | CN¥29.47 Million |
| 2009 | 27.44% | 17.39% | 1.15x | 1.38x | CN¥31.30 Million |
| 2010 | 6.90% | 18.06% | 0.36x | 1.05x | CN¥-27.86 Million |
| 2011 | 6.66% | 14.68% | 0.43x | 1.06x | CN¥-29.54 Million |
| 2012 | 8.44% | 16.64% | 0.47x | 1.08x | CN¥-15.05 Million |
| 2013 | 10.30% | 18.95% | 0.44x | 1.23x | CN¥3.24 Million |
| 2014 | 10.49% | 15.95% | 0.54x | 1.22x | CN¥5.49 Million |
| 2015 | 8.04% | 12.56% | 0.57x | 1.13x | CN¥-23.94 Million |
| 2016 | 6.75% | 10.64% | 0.48x | 1.33x | CN¥-40.90 Million |
| 2017 | 8.92% | 13.11% | 0.49x | 1.39x | CN¥-13.12 Million |
| 2018 | 10.82% | 16.00% | 0.51x | 1.32x | CN¥11.20 Million |
| 2019 | 10.61% | 18.30% | 0.47x | 1.23x | CN¥9.38 Million |
| 2020 | 6.66% | 14.32% | 0.39x | 1.18x | CN¥-53.33 Million |
| 2021 | 7.74% | 15.12% | 0.42x | 1.21x | CN¥-39.38 Million |
| 2022 | 8.85% | 18.30% | 0.40x | 1.21x | CN¥-21.80 Million |
| 2023 | 10.44% | 21.46% | 0.41x | 1.19x | CN¥8.71 Million |
| 2024 | 10.00% | 21.93% | 0.39x | 1.16x | CN¥-93.79K |
| 2025 | 8.32% | 19.07% | 0.39x | 1.13x | CN¥-39.97 Million |
Industry Comparison
This section compares Hunan Hansen Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Hansen Pharmaceutical Co Ltd (002412) | CN¥2.42 Billion | 21.39% | 0.13x | $436.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syru… Read more